Regulatory T Cells (Tregs) in Polymorphic Light Eruption
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00555178|
Recruitment Status : Completed
First Posted : November 8, 2007
Last Update Posted : May 7, 2015
|Condition or disease|
|Polymorphic Light Eruption Psoriasis Atopic Eczema|
PLE patients will be recruited through the Photodermatology Unit of the Department of Dermatology, Medical University of Graz, Graz, Austria. Eligible patients will be identified through diagnosis-related computer-assisted search in the electronic patient chart system of the Unit. The diagnosis of PLE will be verified by patient's history, clinical symptoms, histologic findings, laboratory studies and/or phototesting procedures.
The levels and function of Tregs, memory T cells, neutrophils, mast cells, Langerhans cells, cytokine and chemokine profiles, vitamin D levels in the blood and/or skin will be studied in PLE patients compared to control groups. Volunteers of four groups will be enrolled in this study: i) patients with PLE undergoing preventive medical UV photohardening in spring; ii) PLE patients not undergoing preventive UV photohardening; iii) healthy control subjects; and iv) patients with other diseases (including psoriasis, atopic dermatitis, and other conditions) undergoing therapeutic phototherapy.
Blood will be taken by venous puncture (mainly of a cubital vein) from the individual study participants at four defined time points during the year: (i) spring (March to April) (before medical photohardening in PLE patients); (ii) spring/early summer (April to June) (immediately after medical photohardening of PLE patients); (iii) late summer (August to September); and (iv) late fall (November to December). In addition, optional skin biopsies will be taken to study the parameters listed above. The statistical power analysis (alpha 0.05; power 0.8; assumed difference in Treg level/function of 30% among groups; based on the data by Myara et al., 2005) revealed that 23 patients (21+2 expected drop-outs) need to be enrolled per patient group. All patients of the non-PLE groups will be sex- and age (plus/minus 5 years)-matched to the PLE subjects.
|Study Type :||Observational|
|Estimated Enrollment :||92 participants|
|Official Title:||Regulatory T Cells (Tregs) in Polymorphic Light Eruption|
|Study Start Date :||March 2008|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
Patients with polymorphic light eruption without medical photohardening treatment
Patients with polymorphic light eruption treated with medical photohardening
Patients with other disorders (including psoriasis) treated with phototherapy
Normal healthy subjects
- Treg level and function [ Time Frame: Prospective ]
- Blood and/or skin cytokine and chemokine levels, vitamin D status, and other immunoregulatory parameters (see above) [ Time Frame: prospective ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00555178
|Medical University of Graz, Department of Dermatology|
|Graz, Austria, 8036|
|Medical University of Graz|
|Graz, Austria, A-8036|
|Principal Investigator:||Peter Wolf, MD||Medical University of Graz|